Home LiteratureArticle Details
PMID: 9272582 Published · ppublish English Journal Article

Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

MMWR. Morbidity and mortality weekly report ·Vol. 46 ·No. 33 ·1997-08-22 ·Pages 765-6

Centers for Disease Control and Prevention CDC

Abstract

Staphylococcus aureus is one of the most common causes of both hospital- and community-acquired infections worldwide, and the antimicrobial agent vancomycin has been used to treat many S. aureus infections, particularly those caused by methicillin-resistant S. aureus (MRSA). In 1996, the first documented case of infection caused by a strain of S. aureus with intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 microg/mL) was reported from Japan. This report describes the first isolation of VISA from a patient in the United States, which may be an early warning that S. aureus strains with full resistance to vancomycin will emerge.

MeSH Terms
Anti-Bacterial Agents/pharmacology Drug Resistance, Microbial Humans Microbial Sensitivity Tests Peritonitis/drug therapy,microbiology Staphylococcal Infections/drug therapy,microbiology Staphylococcus aureus/drug effects United States Vancomycin/pharmacology
Chemicals
Anti-Bacterial Agents Vancomycin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Centers for Disease Control and Prevention (CDC)
Article Info
Journal
MMWR. Morbidity and mortality weekly report
Abbr.
MMWR Morb Mortal Wkly Rep
ISSN
0149-2195
Published
1997-08-22
Pages
765-6
Language
English
Region
United States
NLM ID
7802429
Subset
IM
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]